TipRanks
Go Ultimate55% OFF

Adaptimmune Therapeutics (ADAPY) Revenue

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had a revenue of 13.68M in the quarter ending Jun 30, 2025, with 87.74%. This bring the company's revenue in the last twelve months to 65.08M, Decreased 63.77%. In the fiscal year ending Dec 31, 2024, Adaptimmune Therapeutics had annual revenue of 178.03M with 195.34% growth.

Revenue (ttm)
65.08M
Revenue Growth
―
P/S Ratio
0.03
Revenue/Employee
$654,529
Employees
272
Market Cap
$6.10M

Revenue Chart

Adaptimmune Therapeutics Revenue - Annual

050M100M150M200M37.83M59.51M1.12M3.96M6.15M27.15M60.28M178.03M20172018201920202021202220232024
Revenue History
Download to Excel
ADAPY revenue history
Fiscal End DateRevenueChangeGrowth
Dec 31, 2024178.03M117.75M195.34%
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 20191.12M-58.38M-98.11%
Dec 31, 201859.51M21.67M57.28%
Dec 31, 201737.83M――
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Related stocks
CompanyRevenue
ADAPY65.08M
BCAB8.50M
SNTI55.00K
XLO64.09M